{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:34:16Z","timestamp":1792096456507,"version":"4.4.0"},"reference-count":107,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n                    Thrombotic microangiopathy (TMA) is a challenging and serious complication of kidney transplantation that significantly affects graft and patient survival, occurring in 0.8%\u201315% of transplant recipients. TMA is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury due to endothelial damage and microthrombi formation in small vessels. However, clinical features can range from a renal-limited form, diagnosed only on a kidney biopsy, to full-blown systemic manifestations, which include neurologic, gastrointestinal, and cardiovascular injury. TMA can arise because of genetic or acquired defects such as in complement-mediated TMA or can occur in the context of other conditions like infections, autoimmune diseases, or immunosuppressive drugs, where complement activation may also play a role. Recurrent TMA after kidney transplant is almost always complement-mediated, although complement overactivation may also play a role in\n                    <jats:italic toggle=\"yes\">de novo<\/jats:italic>\n                    post-transplant TMAs associated with ischemia-reperfusion injury, immunosuppressive drugs, antibody-mediated rejection, viral infections, and relapse of autoimmune diseases, such as antiphospholipid antibody syndrome. Differentiating between a complement-mediated process and one triggered by other factors is often challenging but critical to minimize allograft damage because the former is nonresponsive to supportive therapy, needs long-term anticomplement therapy, and has a high risk of recurrence. Given the central role of complement and effect of genetic defects on the risk of recurrence in many forms of post-transplant TMA, genetic testing for complement disorders is key for proper diagnosis and management. Given that complement activation may also play a role in a subset of TMAs associated with other conditions, prompt recognition and timely initiation of anticomplement therapy is equally important. In addition, TMA associated with noncomplement genes, often part of a broader syndromic process with distinct clinical features, has also been described. Early identification and treatment are essential to prevent graft failure and other severe complications. This review explores the pathophysiologic mechanisms underlying various post-transplant TMAs.\n                  <\/jats:p>","DOI":"10.1681\/asn.0000000645","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T12:05:06Z","timestamp":1738325106000},"page":"940-951","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Post-transplant Thrombotic Microangiopathy"],"prefix":"10.1681","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-238X","authenticated-orcid":false,"given":"Anuja","family":"Java","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-2691","authenticated-orcid":false,"given":"Matthew A.","family":"Sparks","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"},{"name":"Renal Section, Durham VA Health Care System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4718-0072","authenticated-orcid":false,"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom"},{"name":"National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"7","key":"B1-20260114","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med."},{"issue":"suppl 1","key":"B2-20260114","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1182\/blood-2018-99-117723","article-title":"Clinical associations, treatment, and outcomes of renal-limited thrombotic microangiopathy","volume":"132","author":"Saba","year":"2018","journal-title":"Blood."},{"issue":"6","key":"B3-20260114","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.kint.2017.02.025","article-title":"Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?","volume":"91","author":"Van Laecke","year":"2017","journal-title":"Kidney Int."},{"key":"B4-20260114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fped.2014.00097","article-title":"Extra-renal manifestations of complement-mediated thrombotic microangiopathies","volume":"2","author":"Hofer","year":"2014","journal-title":"Front Pediatr."},{"issue":"3","key":"B5-20260114","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","article-title":"An expert discussion on the atypical hemolytic uremic syndrome nomenclature\u2014identifying a road map to precision: a report of a National Kidney Foundation Working Group","volume":"106","author":"Nester","year":"2024","journal-title":"Kidney Int."},{"issue":"1","key":"B6-20260114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep."},{"key":"B7-20260114","doi-asserted-by":"crossref","first-page":"642864","DOI":"10.3389\/fmed.2021.642864","article-title":"Thrombotic microangiopathy after kidney transplantation: an underdiagnosed and potentially reversible entity","volume":"8","author":"\u00c1vila","year":"2021","journal-title":"Front Med."},{"issue":"6","key":"B8-20260114","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","article-title":"Outcomes from the international society of nephrology hemolytic uremic syndromes international forum","volume":"106","author":"Kavanagh","year":"2024","journal-title":"Kidney Int."},{"key":"B9-20260114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-pathol-012615-044145","article-title":"Complement dysregulation and disease: insights from contemporary genetics","volume":"12","author":"Liszewski","year":"2017","journal-title":"Annu Rev Pathol."},{"key":"B10-20260114","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-072211-110606","article-title":"Defective complement inhibitory function predisposes to renal disease","volume":"64","author":"Java","year":"2013","journal-title":"Annu Rev Med."},{"issue":"10","key":"B11-20260114","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.2215\/CJN.01710216","article-title":"All things complement","volume":"11","author":"Thurman","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B12-20260114","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The central role of the alternative complement pathway in human disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J Immunol."},{"issue":"4","key":"B13-20260114","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2014","journal-title":"Semin Thromb Hemost."},{"issue":"4","key":"B14-20260114","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int."},{"issue":"6","key":"B15-20260114","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol."},{"issue":"6","key":"B16-20260114","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood.2022019361","article-title":"Mutations in atypical hemolytic uremic syndrome provide evidence for the role of calcium in complement factor I","volume":"142","author":"Java","year":"2023","journal-title":"Blood."},{"issue":"1","key":"B17-20260114","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"13","key":"B18-20260114","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood."},{"issue":"2","key":"B19-20260114","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood."},{"issue":"2","key":"B20-20260114","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"B21-20260114","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2025.01.026","article-title":"Thrombotic microangiopathy after kidney transplantation: insights into genetic etiology and clinical outcomes","author":"Merzkani","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B22-20260114","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the Blood Center of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol."},{"key":"B23-20260114","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fmed.2020.00212","article-title":"An update in drug-induced thrombotic microangiopathy","volume":"7","author":"Chatzikonstantinou","year":"2020","journal-title":"Front Med."},{"issue":"11","key":"B24-20260114","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med."},{"issue":"24","key":"B25-20260114","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)."},{"issue":"10","key":"B26-20260114","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2010030295","article-title":"Glomerular structure and function require paracrine, not autocrine, VEGF\u2013VEGFR-2 signaling","volume":"21","author":"Sison","year":"2010","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B27-20260114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B28-20260114","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1172\/JCI86418","article-title":"VEGF regulates local inhibitory complement proteins in the eye and kidney","volume":"127","author":"Keir","year":"2017","journal-title":"J Clin Invest."},{"issue":"2","key":"B29-20260114","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Boll\u00e9e","year":"2009","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"B30-20260114","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol."},{"issue":"13","key":"B31-20260114","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","author":"Hunt","year":"2014","journal-title":"N Engl J Med."},{"issue":"24","key":"B32-20260114","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood."},{"issue":"42","key":"B33-20260114","doi-asserted-by":"crossref","first-page":"eaav7501","DOI":"10.1126\/sciimmunol.aav7501","article-title":"Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2","volume":"4","author":"Duncan","year":"2019","journal-title":"Sci Immunol."},{"issue":"1","key":"B34-20260114","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"B35-20260114","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med."},{"issue":"7","key":"B36-20260114","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.transproceed.2014.07.062","article-title":"Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation","volume":"46","author":"Nava","year":"2014","journal-title":"Transplant Proc."},{"issue":"6","key":"B37-20260114","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1046\/j.1523-1755.1999.00492.x","article-title":"Cyclosporine-associated thrombotic microangiopathy in renal allografts","volume":"55","author":"Zarifian","year":"1999","journal-title":"Kidney Int."},{"issue":"7","key":"B38-20260114","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.ajt.2024.01.029","article-title":"De novo thrombotic microangiopathy after kidney transplantation in adults: interplay between complement genetics and multiple endothelial injury","volume":"24","author":"Dessaix","year":"2024","journal-title":"Am J Transplant."},{"key":"B39-20260114","doi-asserted-by":"crossref","first-page":"891513","DOI":"10.3389\/fmed.2023.891513","article-title":"The loss of glycocalyx integrity impairs complement factor H binding and contributes to cyclosporine-induced endothelial cell injury","volume":"10","author":"Teoh","year":"2023","journal-title":"Front Med."},{"key":"B40-20260114","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.thromres.2023.02.012","article-title":"Eculizumab in the management of drug-induced thrombotic microangiopathy: a scoping review of the literature","volume":"224","author":"Zafar","year":"2023","journal-title":"Thromb Res."},{"issue":"2","key":"B41-20260114","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1203\/00006450-200108000-00002","article-title":"Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome","volume":"50","author":"Proulx","year":"2001","journal-title":"Pediatr Res."},{"issue":"11","key":"B42-20260114","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00467-017-3783-4","article-title":"Influenza-associated thrombotic microangiopathies","volume":"33","author":"Bitzan","year":"2018","journal-title":"Pediatr Nephrol."},{"issue":"2","key":"B43-20260114","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5144\/1658-3876.2011.51","article-title":"Viral-associated thrombotic microangiopathies","volume":"4","author":"Lopes da Silva","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther."},{"issue":"11","key":"B44-20260114","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1537-2995.2008.01871.x","article-title":"A severe case of atypical hemolytic uremic syndrome associated with pneumococcal infection and T activation treated successfully with plasma exchange","volume":"48","author":"Hopkins","year":"2008","journal-title":"Transfusion."},{"issue":"2","key":"B45-20260114","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr."},{"issue":"6","key":"B46-20260114","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.V1161132","article-title":"Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation","volume":"11","author":"Murer","year":"2000","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"B47-20260114","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/tri.12582","article-title":"Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature","volume":"28","author":"Java","year":"2015","journal-title":"Transpl Int."},{"issue":"15","key":"B48-20260114","doi-asserted-by":"crossref","first-page":"e140711","DOI":"10.1172\/jci.insight.140711","article-title":"The complement system in COVID-19: friend and foe?","volume":"5","author":"Java","year":"2020","journal-title":"JCI Insight."},{"issue":"17","key":"B49-20260114","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa010319","article-title":"BK-related polyomavirus vasculopathy in a renal-transplant recipient","volume":"345","author":"Petrogiannis-Haliotis","year":"2001","journal-title":"New Engl J Med."},{"issue":"4","key":"B50-20260114","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijt.2015.10.008","article-title":"BK virus-related thrombotic microangiopathy in a kidney transplant recipient","volume":"9","author":"Bulut","year":"2015","journal-title":"Indian J Transplant."},{"issue":"4","key":"B51-20260114","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/bloodadvances.2021004933","article-title":"Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults","volume":"6","author":"Vasu","year":"2022","journal-title":"Blood Adv."},{"key":"B52-20260114","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.3389\/ti.2023.11590","article-title":"Thrombotic microangiopathy in the renal allograft: results of the TMA Banff working group consensus on pathologic diagnostic criteria","volume":"36","author":"Afrouzian","year":"2023","journal-title":"Transpl Int."},{"issue":"1","key":"B53-20260114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01487740","article-title":"Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells","volume":"20","author":"Foreman","year":"1996","journal-title":"Inflammation."},{"issue":"12","key":"B54-20260114","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.4049\/jimmunol.178.12.7911","article-title":"RNA interference elucidates the role of focal adhesion kinase in HLA class I-mediated focal adhesion complex formation and proliferation in human endothelial cells","volume":"178","author":"Jin","year":"2007","journal-title":"J Immunol."},{"issue":"23","key":"B55-20260114","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1161\/CIRCULATIONAHA.113.002972","article-title":"Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-\u03baB signaling in endothelial cells","volume":"128","author":"Jane-Wit","year":"2013","journal-title":"Circulation."},{"issue":"4","key":"B56-20260114","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.humimm.2004.01.002","article-title":"Anti-HLA class I antibody-mediated activation of the PI3K\/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells","volume":"65","author":"Jin","year":"2004","journal-title":"Hum Immunol."},{"issue":"10","key":"B57-20260114","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial","volume":"19","author":"Marks","year":"2019","journal-title":"Am J Transplant."},{"issue":"11","key":"B58-20260114","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/TP.0000000000002639","article-title":"Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases","volume":"103","author":"Tan","year":"2019","journal-title":"Transplantation."},{"issue":"8","key":"B59-20260114","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.transproceed.2022.08.008","article-title":"Lack of efficacy and safety of eculizumab for treatment of antibody-mediated rejection following renal transplantation","volume":"54","author":"Heo","year":"2022","journal-title":"Transplant Proc."},{"issue":"suppl 3","key":"B60-20260114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ajt.14584","article-title":"Antibody-mediated rejection: new approaches in prevention and management","volume":"18","author":"Montgomery","year":"2018","journal-title":"Am J Transplant."},{"issue":"9","key":"B61-20260114","doi-asserted-by":"crossref","first-page":"104981","DOI":"10.1016\/j.isci.2022.104981","article-title":"Versatile enzymology and heterogeneous phenotypes in cobalamin complementation type C disease","volume":"25","author":"Esser","year":"2022","journal-title":"iScience."},{"issue":"5","key":"B62-20260114","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ekir.2018.05.015","article-title":"Cobalamin C deficiency induces a typical histopathological pattern of renal arteriolar and glomerular thrombotic microangiopathy","volume":"3","author":"Lemoine","year":"2018","journal-title":"Kidney Int Rep."},{"issue":"27","key":"B63-20260114","doi-asserted-by":"crossref","first-page":"17012","DOI":"10.1074\/jbc.272.27.17012","article-title":"Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase","volume":"272","author":"Upchurch","year":"1997","journal-title":"J Biol Chem."},{"issue":"1","key":"B64-20260114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1389200052997357","article-title":"Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function","volume":"6","author":"Weiss","year":"2005","journal-title":"Curr Drug Metab."},{"issue":"5","key":"B65-20260114","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/ckj\/sfx081","article-title":"Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea","volume":"10","author":"Brocklebank","year":"2017","journal-title":"Clin Kidney J."},{"issue":"9","key":"B66-20260114","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jmedgenet-2011-100286","article-title":"Novel inborn error of folate metabolism: identification by exome capture and sequencing of mutations in the MTHFD1 gene in a single proband","volume":"48","author":"Watkins","year":"2011","journal-title":"J Med Genet."},{"issue":"9","key":"B67-20260114","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s004310051190","article-title":"Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency","volume":"158","author":"Labrune","year":"1999","journal-title":"Eur J Pediatr."},{"issue":"16","key":"B68-20260114","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood."},{"issue":"9","key":"B69-20260114","doi-asserted-by":"crossref","first-page":"e146959","DOI":"10.1172\/jci.insight.146959","article-title":"Loss of diacylglycerol kinase \u03b5 causes thrombotic microangiopathy by impairing endothelial VEGFA signaling","volume":"6","author":"Liu","year":"2021","journal-title":"JCI Insight."},{"issue":"6","key":"B70-20260114","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank","year":"2020","journal-title":"Kidney Int."},{"issue":"9","key":"B71-20260114","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","article-title":"Complement mutations in diacylglycerol kinase-\u03b5\u2013associated atypical hemolytic uremic syndrome","volume":"9","author":"S\u00e1nchez Chinchilla","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B72-20260114","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet."},{"issue":"10","key":"B73-20260114","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.tibs.2013.06.013","article-title":"Threading the barrel of the RNA exosome","volume":"38","author":"Schneider","year":"2013","journal-title":"Trends Biochem Sci."},{"issue":"4","key":"B74-20260114","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cell.2015.04.034","article-title":"RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity","volume":"161","author":"Pefanis","year":"2015","journal-title":"Cell."},{"issue":"8","key":"B75-20260114","doi-asserted-by":"crossref","first-page":"e202000678","DOI":"10.26508\/lsa.202000678","article-title":"RNA exosome mutations in pontocerebellar hypoplasia alter ribosome biogenesis and p53 levels","volume":"3","author":"M\u00fcller","year":"2020","journal-title":"Life Sci Alliance."},{"issue":"3","key":"B76-20260114","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cge.14105","article-title":"A splice site mutation in the TSEN2 causes a new syndrome with craniofacial and central nervous system malformations, and atypical hemolytic uremic syndrome","volume":"101","author":"Canpolat","year":"2022","journal-title":"Clin Genet."},{"issue":"3","key":"B77-20260114","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"B78-20260114","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1086\/518257","article-title":"Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans","volume":"80","author":"Yang","year":"2007","journal-title":"Am J Hum Genet."},{"issue":"6","key":"B79-20260114","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3899\/jrheum.220752","article-title":"The role of complement in autoimmune disease-associated thrombotic microangiopathy and the potential for therapeutics","volume":"50","author":"Java","year":"2023","journal-title":"J Rheumatol."},{"issue":"4","key":"B80-20260114","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1186\/ar4016","article-title":"Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome","volume":"14","author":"Foltyn Zadura","year":"2012","journal-title":"Arthritis Res Ther."},{"issue":"16","key":"B81-20260114","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv."},{"issue":"11","key":"B82-20260114","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2017.09.012","article-title":"Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review","volume":"16","author":"Lee","year":"2017","journal-title":"Autoimmun Rev."},{"issue":"11","key":"B83-20260114","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation","volume":"11","author":"Hadaya","year":"2011","journal-title":"Am J Transplant."},{"key":"B84-20260114","doi-asserted-by":"crossref","first-page":"775280","DOI":"10.3389\/fmed.2021.775280","article-title":"Clinicopathologic implications of complement genetic variants in kidney transplantation","volume":"8","author":"Ren","year":"2021","journal-title":"Front Med."},{"issue":"6","key":"B85-20260114","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"B86-20260114","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus."},{"issue":"7","key":"B87-20260114","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome","volume":"55","author":"Barratt-Due","year":"2016","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"B88-20260114","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"B89-20260114","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"12","key":"B90-20260114","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/art.41460","article-title":"Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome","volume":"72","author":"Zuo","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"B91-20260114","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tmrv.2022.09.002","article-title":"Emerging therapies in antiphospholipid syndrome","volume":"36","author":"Hubben","year":"2022","journal-title":"Transfus Med Rev."},{"issue":"11","key":"B92-20260114","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/rheumatology\/key228","article-title":"Eculizumab for catastrophic antiphospholipid syndrome\u2014a case report and literature review","volume":"57","author":"Guillot","year":"2018","journal-title":"Rheumatology."},{"issue":"8","key":"B93-20260114","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"18","key":"B94-20260114","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med."},{"issue":"1","key":"B95-20260114","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/2175-8239-jbn-3807","article-title":"Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology","volume":"40","author":"Zuckerman","year":"2018","journal-title":"J Bras Nefrol."},{"issue":"1","key":"B96-20260114","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13075-016-1168-x","article-title":"Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis","volume":"18","author":"Okr\u00f3j","year":"2016","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"B97-20260114","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ackd.2019.11.002","article-title":"Complement and renal thrombotic microangiopathy associated with hypertension and scleroderma","volume":"27","author":"Zuckerman","year":"2020","journal-title":"Adv Chronic Kidney Dis."},{"issue":"7","key":"B98-20260114","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3390\/jcm9072136","article-title":"Neutrophil extracellular traps generation relates with early stage and vascular complications in systemic sclerosis","volume":"9","author":"Didier","year":"2020","journal-title":"J Clin Med."},{"issue":"451","key":"B99-20260114","doi-asserted-by":"crossref","first-page":"eaao3089","DOI":"10.1126\/scitranslmed.aao3089","article-title":"Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis","volume":"10","author":"Maugeri","year":"2018","journal-title":"Sci Transl Med."},{"issue":"1","key":"B100-20260114","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12882-023-03416-7","article-title":"De novo normotensive scleroderma renal crisis six years after living-donor renal transplantation in a patient with overlapping systemic sclerosis\/systemic lupus erythematosus syndrome: a case report","volume":"24","author":"Sanada","year":"2023","journal-title":"BMC Nephrol."},{"issue":"9","key":"B101-20260114","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.autrev.2018.03.012","article-title":"Therapy of scleroderma renal crisis: state of the art","volume":"17","author":"Zanatta","year":"2018","journal-title":"Autoimmun Rev."},{"issue":"23","key":"B102-20260114","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"issue":"6","key":"B103-20260114","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int."},{"issue":"12","key":"B105-20260114","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1007\/s00277-023-05439-4","article-title":"Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD","volume":"102","author":"McBride","year":"2023","journal-title":"Ann Hematol."},{"issue":"4","key":"B106-20260114","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/TP.0000000000004355","article-title":"Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome","volume":"107","author":"Glover","year":"2023","journal-title":"Transplantation."},{"issue":"12","key":"B107-20260114","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant."},{"key":"B108-20260114","article-title":"Kidney transplantation in patients with aHUS: a comparison of eculizumab prophylaxis versus rescue therapy","author":"Duineveld","year":"2024","journal-title":"Transplantation."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:45:39Z","timestamp":1786131939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000000645","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}